2024
In June, Aqilion regains the rights to the TAK1 program from Merck.
In May, Aqilion nominates a new project with the kinase PKCtheta as a drug target in its pipeline.
History
2023
In October, Aqilion reported positive results from the ARIA-1 Phase 1 study in healthy subjects. The drug candidate AQ280 was well tolerated, and the achieved single and multidose exposure is in line with estimates of a therapeutically effective range based on preclinical models.
In August, Aqilion successfully completed the ARIA-1 Phase 1 study with the drug candidate AQ280 (Regulus program) in healthy subjects, in single dose and repeated doses.
In February, Aqilion announces pre-clinical licensing and strategic research collaboration with Merck.
2022
Aqilion reinforces its position as a biotech company.
The drug candidate AQ312, a new treatment of chronic inflammatory bowel diseases (IBD), strengthens and complements the pipeline.
In August, Aqilion started a Phase 1 safety study with the drug candidate AQ280 (Regulus program) in healthy volunteers.
2021
Aqilion acquires a phase-1 ready anti-inflammatory program, now Regulus, from LEO Pharma.
The Alnitak program expands by the Alnitak CNS project.
The early oncology research project Alhena closes.
2020
Aqilion initiates the Polaris program aiming at developing the first of its class compounds to prevent harmful effects of chronic inflammation.
Aqilion becomes a public limited company.
The headquarters move to new premises in Helsingborg and Aqilion opens an affiliate office at Medicon Village in Lund.
2019
The pipeline strengthens with two preclinical programs in inflammation, Alhena and Alnitak.
Aqilion receives SEK 100 million through conversion of outstanding warrants.
PULS changes its name to AQILION AB as a step toward repositioning the company as a biotech company with a pipeline targeting inflammation.
2017
Sarah Fredriksson joins as CEO.
AcuCort is listed on Spotlight and legacy PULS remains the principal owner.
2014
The project company LIDDS is listed on Nasdaq First North Growth market.
2011
Oncorena targeting advanced kidney cancer is founded.
2007
Laccure, a female health project, is founded.
2006
AcuCort AB with focus on allergy is founded.
2003
Legacy PULS becomes operational. LIDDS AB is founded followed by the start-up of a number of projects and project companies through the coming years.
2002
Legacy PULS (Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) is founded in Helsingborg, Sweden, by a group of people with backgrounds in the pharmaceutical industry and research.
